Get the Stockscreener App
11.79
0.08%
-0.01
After Hours:
11.79
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr Reddys Laboratories Ltd Adr stock is traded at $11.79, with a volume of 3.23M.
It is down -0.08% in the last 24 hours and down -19.58% over the past month.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
See More
Previous Close:
$11.80
Open:
$11.8
24h Volume:
3.23M
Relative Volume:
1.19
Market Cap:
$9.82B
Revenue:
$3.81B
Net Income/Loss:
$485.75M
P/E Ratio:
20.07
EPS:
0.5873
Net Cash Flow:
$175.50M
1W Performance:
-6.43%
1M Performance:
-19.58%
6M Performance:
-13.82%
1Y Performance:
-19.85%
1-Day Range:
$11.68
$11.98
1-Week Range:
$11.36
$12.74
52-Week Range:
$11.36
$15.67
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
11.79 | 9.83B | 3.81B | 485.75M | 175.50M | 0.5873 |
TAK
Takeda Pharmaceutical Co Adr
|
17.24 | 53.71B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.78 | 42.76B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.81 | 36.31B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.35 | 31.26B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
528.47 | 26.37B | 3.17B | 1.29B | 1.01B | 27.09 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-26 | Downgrade | Goldman | Neutral → Sell |
| Jun-05-25 | Upgrade | HSBC Securities | Hold → Buy |
| Dec-19-24 | Downgrade | Nomura | Buy → Neutral |
| Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
| Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
| May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-30-23 | Initiated | JP Morgan | Underweight |
| Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-03-22 | Resumed | BofA Securities | Neutral |
| Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-18-20 | Upgrade | Investec | Sell → Hold |
| Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
| Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
| Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-20-19 | Initiated | Deutsche Bank | Hold |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
| Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
| Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
| Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
| Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
| Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News
Dr. Reddy’s Labs ADR earnings missed by $0.03, revenue fell short of estimates By Investing.com - Investing.com South Africa
Dr Reddy's share price: Why this stock plunged 9% today; more downside ahead? - Business Today
Dr. Reddy's Labs shares fall 4% after weak Q1 results; Profit slumps 69%, margins shrink - Business Upturn
Dr Reddy's Labs share price to track 9% ADR fall; targets by CLSA, Nomura, Goldman Sachs, Citi, others - Business Today
Q1 Results LIVE Updates: Infosys, Cipla, IndiGo report today; Dr Reddy's ADR tanks 10% - CNBC TV18
Dr. Reddy's Laboratories shares fall 7% as most analysts remain bearish after Q1 earnings miss - CNBC TV18
Dr. Reddy’s Labs ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com India
Dr. Reddy's Earnings: Reduced Lenalidomide Sales and Semaglutide Challenge Mark a Weak Start to Year - Morningstar
Dr. Reddy's Starts Year on Weak Ground as Lenalidomide and Semaglutide Impacts Weigh on Results - Morningstar
Earnings call transcript: Dr. Reddy’s misses Q1 2026 EPS forecast as stock falls 8% - Investing.com
Dr Reddy’s ADR falls 5% as profit drops sharplyCheck details - CNBC TV18
Dr Reddy’s ADR falls over 5% after Q1 results miss analyst estimates despite already muted expectations - Business Upturn
ASML Holding N.V. Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies - GlobeNewswire Inc.
Price to earnings forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Korea’s SK Hynix makes history in US – raises $26.5 billion in largest foreign debut - financialexpress.com
SK Hynix plans to price its US listing at $149 - financialexpress.com
Dr Reddy's Shares Slide Over 6% After Semaglutide Batch Quality Concern - NDTV Profit
Dr. Reddy's Labs ADR highlights its global generics footprint as investors track U.S. healthcare dem - ad-hoc-news.de
Dr. Reddy's Labs ADR highlights global generics reach. Investors look at U.S. listing context - Ad-hoc-news.de
RDY News | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call - Sahm
Eli Lilly Upgraded, Carvana Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy’s Laboratories files FY26 annual report with US SEC - scanx.trade
RDDA Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Enterprise value to EBITDA forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Dr. Reddy's Labs ADR files Form 20-F, shares stay tied to US pharma peers - AD HOC NEWS
Enterprise value to EBIT forward of Dr. Reddy's Laboratories Ltd. Sponsored ADR – MUN:RDDA - TradingView
Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR - TradingView
Dr. Reddy’s files 2026 annual report with the SEC - Stock Titan
659157 Forecast — Price Target — Prediction for 2027 - TradingView
Form 6K DR REDDYS LABORATORIES LTD For: 22 June By Investing.com - Investing.com Nigeria
Form 6K Kinross Gold Corp For: 22 June By Investing.com - Investing.com Nigeria
Dr. Reddy’s (NYSE: RDY) allots 6,730 ESOP shares to employees - Stock Titan
Why Dr. Reddy's Venlafaxine XR capsules quietly matter for everyday patients - AD HOC NEWS
Dr. Reddy’s Allots 6,730 ESOP Shares, Expands Issued Capital - TipRanks
Why Dr. Reddy’s Celevida Maxx matters for Indian diabetics - AD HOC NEWS
NIFTY50, SENSEX today: Wall Street cues, FII activity, key things to know before markets open on June 19 - Upstox
Dr. Reddy's Labs (ADR) Stock (US2565981035): Earnings and valuation keep the ADR in focus - ad-hoc-news.de
Dr. Reddy's Laboratories Ltd Stock (INE089A01023): U.S. Bosutinib Launch And Pre-market Drop Put ADR - Ad-hoc-news.de
Dr. Reddy's Laboratories stock (INE089A01023): focus on recent FDA progress and US generics growth - Ad-hoc-news.de
With Lenalidomide Headwinds Behind, Dr. Reddy's Turns to Biosimilars and Consumer Health for Growth - Morningstar
Dr. Reddy’s (NYSE: RDY) allots 12,100 ESOP shares, updates capital - Stock Titan
Dr. Reddy’s Laboratories issues 12,100 equity shares under stock options scheme - Business Upturn
Topicus submits revised $2.00 per share proposal for ReadyTech By Investing.com - Investing.com UK
Topicus submits revised $2.00 per share proposal for ReadyTech - Investing.com UK
RDY - Finviz
Dr Reddys Laboratories Ltd Adr Stock (RDY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):